Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

Google plans expanded medicine search

Will start showing side effects and related drugs as part of 'knowledge graph'

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Doctors.net.uk unveils medical quiz apps

Apps cover therapeutics, cardiology, general internal medicines and general practice

- PMLiVE

Merck & Co takes Alzheimer’s prospect into phase II/III trials

Developed to interrupt formation of amyloid plaques

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

US management shake-up at Valeant

New appointments in several senior roles following Medicis acquisition

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Salaries: a figure of speech

Zenopa survey reveals what ‘would be’ medical writers in the UK can expect to earn

- PMLiVE

Bray Leino opens health and wellbeing PR practice

Appoints Hayley Knight to run Rx, OTC and wellbeing services

ABPI London offices

Biosimilars should be routinuely assessed by NICE, says ABPI

Calls for biosimilars to go through full HTA process

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links